Jh-X-119-01 improves survival and decreases immunopathies of LPS-challenged mice. Jh-X-119-01 increases survival of mice at the dose of 5 mg/kg body weight. Survival is further improved when the dose is increased to 10 mg/kg[1].
| Animal Model: | C57BL/6 (20-22 g, male) mice[1] |
| Dosage: | 5 mg/kg and 10 mg/kg |
| Administration: | Intraperitoneally injected; 5 days |
| Result: | Protected mice from LPS (20 mg/kg)-induced sepsis. Survival at day 5 was 13.3% in control group where septic mice were treated by vehicle, while the values were 37.5% and 56.3% for 5 mg/kg and 10 mg/kg. |
